Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

CTS-1027: Phase IIb discontinued

October 31, 2011 7:00 AM UTC

The trial was comparing 15, 30 and 60 mg CTS-1027 twice daily for 24 or 48 weeks plus SOC vs. SOC alone in 114 patients with chronic HCV genotype 1 infection who were null-responders to previous SOC therapy. Conatus said it will continue analysis of low-dose CTS-1027 in the open-label, single arm Phase IIa CTS-1027-04 trial, which completed dosing. Final Phase IIa data are expected next quarter. Conatus has exclusive, worldwide rights to CTS-1027 from Roche, which markets Pegasys and Copegus. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article